GnRH-a和孕三烯酮预防子宫内膜异位症术后复发的对比研究(1)
[摘要] 目的 观察GnRH-a和孕三烯酮预防子宫内膜异位症术后的疗效和不良反应、复发情况。 方法 选取149例我院2007年6月～2009年6月住院经B超和手术治疗的子宫内膜异位症患者，随机分成GnRH-a组96例和孕三烯酮组53例，比较两组的疗效及妊娠率、不良反应情况。 结果 GnRH-a组显效率、改善率与对照组比较差异无统计学意义，但GnRH-a组的复发率明显低于对照组，差异有统计学意义(P < 0.05)。根据r-AFS分期显示，Ⅰ期、Ⅱ期患者的妊娠率显著高于Ⅲ期、Ⅳ期患者，差异有统计学意义(P < 0.01)。GnRH-a组1例出现体重增加，1例出现阴道干涩，不良反应发生率明显低于孕三烯酮组。 结论 GnRH-a预防子宫内膜异位症术后复发疗效满意，安全可靠，疗效优于孕三烯酮，值得临床推广使用。
[关键词] 子宫内膜异位症；GnRH-a；孕三烯酮；复发
[中图分类号] R711.71 [文献标识码] B [文章编号] 1673-9701(2012)16-0039-02
, 百拇医药
GnRH-a and gestrinone to prevent endometrial endometriosis recurrence
FENG Shuqun
The Fourth Wards, Ningbo City Women and Children Hospital in Zhejiang Province, Ningbo 315010, China
[Abstract] Objective To observe efficacy and adverse effects and recurrence of GnRH-a and gestrinone in prevention of endometriosis. Methods A total of 149 patients in our hospital was hospitalized on June 2007 June 2009 by B ultrasound and surgical treatment of endometriosis patients were randomly divided into two groups of GnRH-a group of 96 cases, gestrinone group 53 cases, two groups were compared the efficacy and pregnancy rate of adverse reactions. Results Of GnRH-a group of remarkable efficiency, the rate of improvement with the control group the difference was not significant, but the GnRH-a group the recurrence rate was significantly lower than the control group, the difference was significant (P < 0.05). r-AFS stage, phase Ⅰ, Phase Ⅱ in patients with pregnancy rate was significantly higher than in stage Ⅲ, Ⅳ patients, the difference was significant (P < 0.01). GnRH-a group 1 case of weight gain, and one cases of vaginal dryness, and the incidence of adverse reactions was significantly lower than the gestrinone group. Conclusion GnRH-a to prevent endometriosis postoperative recurrence results were satisfactory, safe and reliable, low recurrence rate, the effective than gestrinone, is worthy of clinical use.
, http://www.100md.com
[Key words] Endometrial endometriosis; GnRH-a; Gestrinone; Recurrence
子宫内膜异位症(endometriosis，EMs)是生育期妇女常见病、多发病，主要以不孕、慢性疼痛及粘连形成为主要特征，该病易复发、难治愈[1]。预防术后复发是临床医生关注的课题之一。促性腺激素释放激素受体(GnRH-R)是介导促性腺激素释放激素(GnRH)功能必不可少的物质。本研究旨在探讨GnRH-a和孕三烯酮预防子宫内膜异位症术后复发的疗效，现报道如下。
1资料与方法
1.1 临床资料
149例患者均为我院2007年6月~2009年6月住院经B超和手术治疗的子宫内膜异位症患者，年龄22~50岁，平均(33.8±4.5)岁，患者术前均有程度不同的月经过多、痛经、下腹痛或腰骶部疼痛及性交痛。根据1985年美国生育学会修订的子宫内膜异位症分期标准(r-AFS)进行分期，Ⅰ期15例，Ⅱ期25例，Ⅲ期74例，Ⅳ期35例。所有病例无肿瘤病史，无高血压、心脏病、糖尿病史，术前3个月内无甾体类激素服用史，血、尿、 肝肾功能正常。将149例患者随机分成两组，GnRH-a组96例，孕三烯酮组53例，两组在年龄、临床症状、r-AFS分期等方面比较差异无统计学意义，具有可比性。两组患者临床资料基线比较见表1。, http://www.100md.com(冯淑群)
[关键词] 子宫内膜异位症；GnRH-a；孕三烯酮；复发
[中图分类号] R711.71 [文献标识码] B [文章编号] 1673-9701(2012)16-0039-02
, 百拇医药
GnRH-a and gestrinone to prevent endometrial endometriosis recurrence
FENG Shuqun
The Fourth Wards, Ningbo City Women and Children Hospital in Zhejiang Province, Ningbo 315010, China
[Abstract] Objective To observe efficacy and adverse effects and recurrence of GnRH-a and gestrinone in prevention of endometriosis. Methods A total of 149 patients in our hospital was hospitalized on June 2007 June 2009 by B ultrasound and surgical treatment of endometriosis patients were randomly divided into two groups of GnRH-a group of 96 cases, gestrinone group 53 cases, two groups were compared the efficacy and pregnancy rate of adverse reactions. Results Of GnRH-a group of remarkable efficiency, the rate of improvement with the control group the difference was not significant, but the GnRH-a group the recurrence rate was significantly lower than the control group, the difference was significant (P < 0.05). r-AFS stage, phase Ⅰ, Phase Ⅱ in patients with pregnancy rate was significantly higher than in stage Ⅲ, Ⅳ patients, the difference was significant (P < 0.01). GnRH-a group 1 case of weight gain, and one cases of vaginal dryness, and the incidence of adverse reactions was significantly lower than the gestrinone group. Conclusion GnRH-a to prevent endometriosis postoperative recurrence results were satisfactory, safe and reliable, low recurrence rate, the effective than gestrinone, is worthy of clinical use.
, http://www.100md.com
[Key words] Endometrial endometriosis; GnRH-a; Gestrinone; Recurrence
子宫内膜异位症(endometriosis，EMs)是生育期妇女常见病、多发病，主要以不孕、慢性疼痛及粘连形成为主要特征，该病易复发、难治愈[1]。预防术后复发是临床医生关注的课题之一。促性腺激素释放激素受体(GnRH-R)是介导促性腺激素释放激素(GnRH)功能必不可少的物质。本研究旨在探讨GnRH-a和孕三烯酮预防子宫内膜异位症术后复发的疗效，现报道如下。
1资料与方法
1.1 临床资料
149例患者均为我院2007年6月~2009年6月住院经B超和手术治疗的子宫内膜异位症患者，年龄22~50岁，平均(33.8±4.5)岁，患者术前均有程度不同的月经过多、痛经、下腹痛或腰骶部疼痛及性交痛。根据1985年美国生育学会修订的子宫内膜异位症分期标准(r-AFS)进行分期，Ⅰ期15例，Ⅱ期25例，Ⅲ期74例，Ⅳ期35例。所有病例无肿瘤病史，无高血压、心脏病、糖尿病史，术前3个月内无甾体类激素服用史，血、尿、 肝肾功能正常。将149例患者随机分成两组，GnRH-a组96例，孕三烯酮组53例，两组在年龄、临床症状、r-AFS分期等方面比较差异无统计学意义，具有可比性。两组患者临床资料基线比较见表1。, http://www.100md.com(冯淑群)